Investors & Media
Dedicated to delivering long-term investment value.
Featured News: CSL and uniQure Win 2023 Prix Galien USA Award
At uniQure, the dual potential for life-changing gene therapies and long-term investor returns creates a unique—and uniquely exciting—opportunity.
Subscribe to receive breaking news alerts about uniQure.Subscribe
Updated stock ticker information for uniQure
(Updated every 15 minutes)
Security and exchange commission filings for uniQure, including quarterly and annual reportsLearn More
Links to key uniQure corporate governance documentsLearn More
No webcasts scheduled. Check back soon.
Corporate Presentation – January 2024View Presentation
December 2023 Huntington's Disease Program Update AMT-130 – Webcast PresentationView Presentation
Virtual Research & Development Event – Nov. 29 event focused on preclinical gene therapy candidate for refractory temporal lobe epilepsy (rTLE) AMT-260 and uniQure AAV manufacturing advancementsView Presentation
CHDI 2022 – Radiographic and clinical progression after motor diagnosis in HD is a function of initial striatal volume and functional scores: a re-analysis of TRACK-HD/TRACK-ON HD MRI images and dataView Presentation
ESGCT 2022 – Enhancing efficacy and specificity of AAV5 capsid via small, intermediate, and large peptide insertionsView Presentation